Molecular pathway analysis of Amyotrophic Lateral Sclerosis by genome-wide expression profiling of human blood and skin fibroblasts.

Molecular pathway analysis of Amyotrophic Lateral Sclerosis by genome-wide expression profiling of human blood and skin fibroblasts. - Biomarkers in ALS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31437

Enrollment

2000

Registered

2006-07-25

Start date

2006-09-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis (ALS) motor neuron disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age > 18 years - Diagnosis of ALS or other ALS-mimic disorder - No cognitive impairement

Exclusion criteria

Exclusion criteria: - Diagnosis unknown

Design outcomes

Primary

Measure	Time frame
Expression profiles will be observed specific for ALS and/or disease progression. Findings can be translated into diagnostic tools. The genetic study will identify DNA variants related to ALS specific expression profiles leading to new insights into the genetic basis of disease susceptibility and progression.	—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results